UBS Oncology Impact Fund L.P.

Insider Reports History

Entity
Company
Location
450 Kendall Street, Cambridge, MA
Signature
/s/ Ansbert Gadicke, managing partner of BioImpact LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by UBS Oncology Impact Fund L.P.:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Cullinan Oncology, Inc. 10%+ Owner Common Stock 7.65M $95.3M $12.46 Sep 16, 2021 Direct
TCR2 THERAPEUTICS INC. 10%+ Owner Common Stock 0 $1.72 Jun 1, 2023 Direct

Insider Reports Filed by UBS Oncology Impact Fund L.P.

Symbol Company Period Transactions Value $ Form Type Date Filed Role
TCRR TCR2 THERAPEUTICS INC. Jun 1, 2023 1 $0 4 Jun 5, 2023 10%+ Owner
CGEM Cullinan Oncology, Inc. Sep 16, 2021 1 -$90.8K 4 Sep 20, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Sep 14, 2021 2 -$395K 4 Sep 16, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Sep 9, 2021 3 -$680K 4 Sep 13, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Sep 3, 2021 3 -$1.42M 4 Sep 8, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Aug 31, 2021 4 -$717K 4 Sep 2, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Aug 23, 2021 2 -$1.3M 4 Aug 31, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Aug 23, 2021 3 -$3.1M 4 Aug 25, 2021 10%+ Owner
CGEM Cullinan Oncology, Inc. Aug 11, 2021 1 -$72.9K 4 Aug 12, 2021 10%+ Owner